MedPath

FAME - a study of the effect of Fampyra on muscle strength in the lower extremities, walking capacity, coordination in the upper extremitties and cognition in multiple sclerosis patients.

Conditions
Multiple Sclerosis
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Registration Number
EUCTR2011-006151-10-DK
Lead Sponsor
Sønderjylland Hospital, department of neurology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with clinically definite multiple sclerosis diagnosed according to the McDonald criteria, aged 18-60 years, EDSS 4-7, pyramidal FS >= 2, able to transport self to University of Southern Denmark in Odense.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 125
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

History of epileptic seizures, relapses of multiple sclerosis or change in disease modifying therapy within 60 days, cancer within five years, uncontrolled hypertension or clinically important cardiac, hepatic, renal or pulmonary disease, pregnancy and concomitant tratment with cimetidine, carvedilol, propranolol or metformine.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: The aim of the trial is to compose a multiple outcome measure trial to<br>1. evaluate the relative sensitivity of a comprehensive series of clinical tests for the identification of multiple sclerosis patients that respond to Fampyra<br>2. compare the effect size of Fampyra treatment when assessed by the Six Spot Step Test;Secondary Objective: ;Primary end point(s): The mean change in six spot step test from day 0 to 28.;Timepoint(s) of evaluation of this end point: 9 weeks
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): Mean changes in Timed 25 Foot Walk, Hip Flexion Dynamometry, Knee Extension Dynamometry, Chair Rise Test, 9 Hole Peg Test and Symbol Digit Modalities Test.;Timepoint(s) of evaluation of this end point: 9 weeks
© Copyright 2025. All Rights Reserved by MedPath